The importance and significance of amantadine-or rimantadine-resistant influenza viruses in immunocompromised patients was studied in a population of adult bone marrow transplant (BMT) recipients and patients with leukemia prospectively cultured for respiratory viruses. Influenza A viruses were isolated from 29 patients with acute respiratory illness (14 BMT recipients and 15 patients with leukemia). Fifteen patients (52%) received amantadine (n Å 4) or rimantadine (n Å 11) therapy. All influenza isolates recovered from six patients shedding virus for §3 days were screened for antiviral susceptibility; resistant isolates were further genetically characterized. Initial influenza isolates were susceptible to amantadine or rimantadine, but subsequent isolates from five of six patients were resistant. Influenza-associated mortality was similar among patients with and without documented antiviral resistance (2 of 5 vs. 5 of 24). We conclude that development of antiviral resistance in immunocompromised individuals should be considered when they have been treated with antivirals and have shed influenza virus for a prolonged period. Isolation procedures should be instituted for all immunocompromised patients with influenza, both during and after therapy with amantadine or rimantadine.
Although influenza A viruses may cause serious disease in development of influenza viruses resistant to amantadine or rimantadine during or following antiviral therapy has been well immunocompromised patients [1] [2] [3] [4] [5] [6] [7] [8] , few data exist on the efficacy of prophylaxis or treatment with amantadine or rimantadine documented in studies of humans [11, 17 -23] . Apparent transmission of resistant viruses to family members or close contacts in these patients. Amantadine and rimantadine (Flumadine; Forest Laboratories, St. Louis) have been shown to be efficacious who were receiving antiviral prophylaxis also has been documented [20 -23] . Although several cases of long-term shedding for the prevention and treatment of infections with influenza A virus in studies of young adults, children, families, and the elof drug-resistant influenza virus in amantadine-or rimantadinetreated immunocompromised patients have been reported prederly [9] [10] [11] [12] [13] , and amantadine or rimantadine has therefore been recommended as prophylaxis and treatment for immunocomviously [24, 25] , the frequency and importance of drug-resistant influenza virus in immunocompromised patients remains unpromised patients [14] . The need for antiviral prophylaxis and chemotherapy against influenza A is important in immunologiclear. Severely immunocompromised patients are an important cally impaired individuals, such as those undergoing bone marrow transplantation or intensive chemotherapy, because influpopulation to study since they may shed viruses for prolonged periods, with or without the use of antiviral therapy, and are enza vaccine administered to these patients is often poorly immunogenic and unlikely to be fully protective [15] .
at risk for serious complications [24 -28] . Prolonged shedding in the setting of antiviral therapy could potentially lead to In the laboratory, resistance to either amantadine or rimantadine has been shown to develop rapidly when influenza A increased rates of development of resistance and nosocomial spread of resistant virus. In this article we describe a prospecviruses are grown in the presence of these drugs. Resistance to one compound confers resistance to the other [16] . The tive study of severely immunocompromised patients who presented with respiratory symptoms during an influenza epidemic period.
were prospectively evaluated [4 -7] . An acute respiratory illwell plates containing MDCK cells. In this assay, viral isolates were added to wells containing varying concentrations of riness was defined as the recent onset (£14 days) of rhinorrhea, nasal or sinus congestion, pharyngitis, coryza, sinusitis, otitis mantadine in minimal essential medium containing trypsin (2 mg/mL) and were allowed to incubate for 24 hours at 36ЊC. media, cough (with or without expectoration), and/or a new radiographic infiltrate. Fever alone was not considered an indiAt the end of this incubation, the contents of each well were transferred to secondary plates containing MDCK cells (but cation for obtaining a respiratory specimen for viral culture. Pneumonia was defined as an acute respiratory illness occurring not rimantadine) and were serially diluted. These plates were incubated for up to 21 days. in association with a new radiographically evident pulmonary infiltrate.
Presence or absence of influenza virus in each well was determined by the addition of a 0.5% suspension of chicken Antiviral therapy (with amantadine, rimantadine, or ribavirin) was prescribed at the discretion of each patient's attending erythrocytes and assessment for hemadsorption. Resistance was defined as viral replication in the presence of a §1-mg/mL physician. During this study period, prophylaxis with amantadine or rimantadine was seldom administered in the patient concentration of rimantadine. A second bioassay with an EIA format was performed by measurement of the nucleoprotein population under study. Treatment with these drugs was initiated during the epidemic period on the basis of clinical sympsynthesis in MDCK cells in the presence of rimantadine (1 mg/mL) [20, 24] . In this confirmatory bioassay, the virus was toms and often before the results of viral culture became available. To the best of our knowledge, influenza vaccine had not considered resistant if nucleoprotein synthesis was inhibited by õ50%. been administered to any of these patients, many of whom presented with acute disease at or around the time of transThe yield-reduction assay was performed to permit nearreal-time identification of resistant virus, and the nasopharynplantation.
geal ELISA was utilized as a confirmatory bioassay on the batched specimens. Correlation between the two assays in this Viral Surveillance study was 100%, except for three viral isolates that could not be grown to a titer sufficient for quantitation by yield reduction. Hospitalized patients were screened daily for signs and symptoms of acute respiratory illness by health care personnel.
PCR-restriction analysis was performed to confirm the bioassay results; reverse transcription -PCR amplification of the M2 A team physician collected respiratory secretions for viral culture [6, 7] . A nasopharyngeal wash, along with a throat swab region of RNA segment 7 was followed by endonuclease digestion with restriction enzymes that differentiate between nucleospecimen, was obtained from cooperative adults. From patients requiring ventilatory support, endotracheal tube secretions were tide sequences typical of susceptible and resistant strains [24] . Correlation of this method with direct sequence analysis has obtained for culture. Bronchoalveolar lavage fluid samples were cultured when available. Asymptomatic patients did not been previously demonstrated [24] . routinely have cultures performed. Cultures were repeated at the request of either the physician caring for the patient or a study physician. The clinical course of many of these patients Results has been previously described [6, 7] .
Respiratory specimens were inoculated into viral transport Infection with influenza A(H3N2) viruses was documented by isolation of virus from 14 BMT recipients and 15 patients media containing veal infusion broth and antibiotics (streptomycin and gentamicin) and were transported on ice to the with leukemia. Initial influenza isolates were cultured from combined nasal wash/throat swab specimens (n Å 24), bronviral diagnostic laboratory. Within 4 hours of collection, the specimens were inoculated into cell culture lines, including choalveolar lavage aliquots (n Å 3), and endotracheal tube aspirates (n Å 2). Fifteen (52%) of the 29 patients with docuMadin-Darby canine kidney (MDCK), continuous rhesus monkey kidney (LLC-MK), human embryonic lung fibroblast (WImented influenza infection received amantadine or rimantadine therapy: 4 received amantadine at a dosage of 100 mg b.i.d., 38), and human epidermoid carcinoma (HEp-2) lines. Hemadsorption was performed on the 3rd, 5th, 10th, and 21st days 10 received rimantadine at a dosage of 100 mg b.i.d., and 1 received both rimantadine and aerosolized ribavirin (6 g/300 after collection. Influenza infection was confirmed by ELISA and by influenza subtyping determined by PCR [29] .
mL, aerosolized over 18 h/d). One additional patient received aerosolized ribavirin only (table 1) . Two or more specimens were obtained from 13 (45%) of
Characterization of Viral Resistance the 29 infected patients 2 -21 days after the original sampling, and influenza virus was again isolated from 6 of these patients. Early-passage frozen viral isolates from patients who had influenza virus recovered on two or more occasions from speci-
The median time between the first and last influenza isolation was 7 days (range, 5 -44 days). In four of six patients, viral mens obtained §3 days apart were tested for rimantadine susceptibility with two different bioassays. In initial testing, a twoshedding was documented for £8 days. Prolonged viral shedding in a BMT recipient (44 days) and a patient undergoing step yield-reduction assay was conducted [27] respiratory tract infection and the initiation of amantadine or rimantadine treatment, no difference was noted between patients infected with resistant virus and those infected with nonchemotherapy for acute lymphocytic leukemia (22 days) (figure resistant virus, in both the BMT recipient group and the leuke-1) was documented. mia group. Furthermore, no differences in outcome (as assessed by mortality or development of resistance) were noted between patients undergoing bone marrow transplantation and those un-
Characteristics of Patients
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dergoing chemotherapy for leukemia. Although no significant differences in clinical presentation or The first influenza isolate from each of the six patients with multiple viral isolates was susceptible to amantadine or rimanoutcome were noted between the BMT recipients and patients with leukemia, some differences between the two populations tadine. One patient had two influenza A isolates obtained prior to antiviral therapy and no isolates thereafter; both virus isolates were seen. Although median ages were not significantly different, more patients with leukemia were older than 50 years (8 of were susceptible to amantadine or rimantadine. Resistance to amantadine or rimantadine was documented in subsequent virus 15 patients with leukemia vs. 2 of 14 BMT recipients; P õ .05). Only 3 (25%) of 12 BMT recipients had radiographic findings isolates from the remaining five patients. Thus, resistant viruses were isolated from 5 of 6 patients who shed influenza virus for compatible with pneumonia at the time of diagnosis, compared with 12 (86%) of 14 patients with leukemia (P Å .005). Despite at least 3 days and from 5 of 16 treated patients (31%).
The first viruses resistant to amantadine or rimantadine were these differences, as well as differences in the type and duration of chemotherapeutic and immunosuppressive regimens used, the isolated between 2 and 15 days following initiation of therapy. Two patients had resistant viruses isolated following £4 days rate of development of resistance appeared to be similar in these two groups of immunocompromised patients. of antiviral therapy. The most common amino acid change occurred at position 31 in the transmembrane region of the M2 Clinical symptoms at the onset of disease were similar in patients with and without resistant influenza virus. Fever and protein, with a substitution of serine for asparagine (n Å 4). A change at position 30 was documented in two patients; in cough were the predominant signs and symptoms in patients with drug-susceptible and -resistant influenza. Shortness of one of these, a virus bearing this mutation was isolated 6 days after isolation of virus with a mutation at codon 31.
breath, need for oxygen supplementation, and detection of / 9c4e$$ju36 05-13-98 05:45:15 cida UC: CID pneumonia by chest radiography were associated with subseamantadine or rimantadine could be related to viral resistance. Overall, mortality rates were relatively high, both in patients quent morbidity and death, regardless of the drug susceptibility of the influenza isolate. No clinical or laboratory factor other who did and in those who did not have resistant influenza isolates documented (2 of 5 and 5 of 24, respectively). than the isolation of a virus during or following the use of Both patients with fatal influenza infection who were shedsymptoms compatible with ongoing viral infection and disease for a period of at least 3 weeks. Two immunosuppressed pading resistant virus were undergoing induction chemotherapy for acute myelocytic leukemia. From one patient (figure 1, tients with ongoing symptomatic disease have also been described: one symptomatic child with severe combined immunopatient 1), amantadine-resistant influenza virus was repeatedly isolated, from 13 days following the initiation of rimantadine deficiency who received a BMT shed resistant virus for 5 weeks, and one adult BMT recipient was shown to shed resistherapy until the day before death. No other pathogens were isolated, and no autopsy was performed. From the second patant virus for 9 days [24] . Both of these patients survived. It is not clear if the detection of resistant isolates is linked to tient (patient 3), amantadine-resistant influenza virus was isolated 2 days before the documented initiation of antiviral therprolonged clinical symptoms in treated immunocompetent individuals [33] . apy. Ribavirin therapy was added to the regimen because of clinical deterioration. Over the following 2 weeks, multiple
Genetic variability was seen in the influenza isolates with documented resistance from one patient. This has been prerespiratory specimens were cultured and did not yield influenza virus.
viously reported with regard to a persistently infected, untreated immunodeficient child [26] and two treated immunocompromised patients [24] . Such variability could be due to heterogeDiscussion neous populations of virus existing in a single patient or even to oscillations of quasispecies [26] . The isolation of amantadine/ The frequency of the development of amantadine/rimantadine-resistant influenza virus infection in immunocompromised rimantadine-resistant influenza virus in the absence of exposure to antiviral therapy also has been reported [34] ; however, the patients is documented for the first time in this study. All influenza isolates from patients with prolonged shedding were occurrence of resistance among wild-type influenza strains is quite uncommon. Our single patient infected with resistant initially susceptible to amantadine or rimantadine, as anticipated. Overall, 4 (27%) of 15 severely immunocompromised virus that was isolated before known drug exposure initially shed influenza virus that was susceptible to amantadine. A patients with influenza who were treated with amantadine or rimantadine subsequently shed resistant influenza virus, and 5 spontaneous mutation may have arisen at this codon, but the possibility that this patient was exposed to antiviral therapy on (83%) of 6 patients with symptomatic disease who shed influenza virus for §3 days had drug-resistant influenza. Similar, an outpatient basis cannot be excluded. Prolonged shedding of drug-resistant influenza virus in a serious consequences of influenza infection occurred in these severely immunocompromised patients whether or not persishospital setting has important implications for nosocomial control of infection. Evidence of potential spread of resistant virus tent shedding with resistant virus was documented.
Although the incidence of drug-resistant influenza in immuin nursing homes and among family members has been well documented [20 -30] . No evidence of nosocomial spread of nocompromised patients has not been previously documented, the incidence of viral resistance developing during or after drug-resistant influenza virus was documented in this study, but the study was not designed to determine if this actually rimantadine/amantadine therapy has been shown to be Ç30% in healthy children [11, 18] . Generally, resistant viruses have occurred. However, if amantadine/rimantadine therapy is being routinely utilized for treatment of influenza in patients in a been isolated 4 -6 days following initiation of therapy in pediatric [11] and family studies [20] , and often they were isolated hospital setting and nosocomial transmission does occur, the potential consequences should be recognized. Furthermore, the from minimally symptomatic individuals who appeared to be recovering from infection.
use of traditional infection control measures -including the vaccination of clinical staff, families of patients, and the paIn ferret [30] and avian [31] models of influenza virus infection, drug-resistant viral infection has been relatively rapidly tients themselves -continues to be an important measure in the control of influenza [14] . induced, and the virus has been shown to be genetically stable, be transmissible, and cause disease similar to that due to wildNo specific antiviral therapy has been proven to be effective for severe lower respiratory tract disease due to influenza. Pritype influenza virus. The mutations responsible for the drugresistant phenotype in this study were the same single amino mary influenza A viral pneumonia has an associated high mortality in the general population; five of 11 otherwise healthy acid changes in the transmembrane portion of the M2 protein previously noted in studies of animal models and humans [16, patients died despite treatment with high-dose oral amantadine (400 -500 mg/[kgrd]) in one study [35] . In prospective studies 32].
Although one case of fatal influenza associated with a probaof severely immunocompromised patients, approximately half the patients infected with influenza developed pneumonia [4 -bly nosocomially transmitted rimantadine-resistant virus in a 72-year old resident of a nursing facility has been described 8], and fatal outcomes were highly associated with the development of pneumonia. Mortality rates also were high among [22] , no fatal cases of rimantadine or amantadine-resistant influenza involving immunocompromised adults have been reyoung pediatric organ transplant recipients infected with influenza who required supplemental oxygen [36] . In our study, the ported. It is interesting that three immunocompromised patients infected with resistant virus in this study had continued clinical development of lower respiratory tract disease in patients with / 9c4e$$ju36 05-13-98 05:45:15 cida UC: CID
